Albin from Bulgaria

Registered at the short selling broker Skilling, 3 minutes ago.

» Try Skilling you too
69% of retail CFD accounts lose money.
Don't show again

Pfizer Inc. (PFE) stock information

Pfizer Inc.

24h Change

0.64 %


Live rate: Market closed

Stock data per Friday 22 May, 2020

New York Stock Exchange
0.24 (+ 0.64%)
US Market is closed

Live Stock price in graph for Pfizer Inc. (PFE)

Data updated continously for PFE, showing up to the 500 most recent 100 data points

  • Latest Volume

    14,972,724 (-10.6 %)

  • Volume prev. day


  • Avg. daily volume


  • Market cap


  • P/E ratio


  • Today high


  • Today low


  • 52 week high


  • 52 week low


  • YTD Change



Latest news about Pfizer Inc.

Below you can find the most recent news posts about Pfizer Inc., primarily from US and UK based news sources.

Research Report with COVID-19 Forecasts – Post-traumatic Stress Disorder Therapeutics Market 2020-2024 | Rising Prevalence of PTSD to Boost Growth | Technavio

Monday, 25 May 2020, 20:30:00
Technavio has been monitoring the post-traumatic stress disorder therapeutics market and it is poised to grow by USD 909.86 million during 2020-2024, progressing at a CAGR of over 9% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. This press release features multimedia. View the full release here: Technavio has announced its latest market research report titled Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market 2020-2024 (Graphic: Business Wire) Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Free Sample Report on COVID-19 Impact The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. AstraZeneca Plc, Azevan Pharmaceuticals Inc., Bionomics Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, H.
— Benzinga Feeds

3 ways to cut through brain fog and stress onset by the coronavirus pandemic, according to a productivity expert

Monday, 25 May 2020, 13:30:00
Alain Hunkins , author of ” CRACKING THE LEADERSHIP CODE: Three Secrets to Building Strong Leaders, ” has designed and facilitated leadership seminars for major corporations including Walmart, General Motors, and Microsoft. People are experiencing allostatic load — the toll that chronic stress takes — onset by the coronavirus pandemic. He recommends people do three things to alleviate allostatic load’s effects: normalize your experience, exercise often, and regularize sleep patterns. Visit Business Insider’s homepage for more stories . When Suzanne got word that she’d be working from home in March, she was ecstatic. Suddenly, her commute time dropped from 75 minutes to 75 seconds. No more people stopping by her desk to ask her questions at random times. Finally, she’d make headway on the big projects that had been stuck on the back burner since last year. Fast forward two months, and those projects are still on the back burner. When asked to describe her work-from-home experience, Suzanne sums it up with one word: Exhausting.
— Business Insider

Major pharma companies rejected a 2017 EU proposal that could let vaccines for viruses like the coronavirus be developed before an outbreak

Monday, 25 May 2020, 10:21:00
A 2017 proposal that would speed up vaccine production in the EU was blocked by major pharmaceutical companies, The Guardian reported . The proposal would fund improvements to testing, potentially allowing approval to be fast-tracked and for vaccines against viruses like the novel coronavirus to be developed before an outbreak begins. But it was rejected by the pharmaceutical companies on the IMI, a body dedicated to improving the EU’s pharmaceutical research. Representatives of a group that includes GlaxoSmithKline, Novartis, Pfizer, and Johnson & Johnson are part of that body, The Guardian reported . The IMI rejected the claim that it has focused on other illnesses to the detriment of the coronavirus, pointing to investments it has made in vaccines and in light of the Ebola outbreak. Companies are now rushing to try and create an effective vaccine to tackle the pandemic. Visit Business Insider’s homepage for more stories . The world’s biggest pharmaceutical companies blocked a 2017 EU proposal that could allow vaccines against viruses like the novel coronavirus to be developed before an outbreak begins, The Guardian reported .
— Business Insider

Oxford University Coronavirus Vaccine Trial Chance Of Success Cut From 80% To Only 50%

Sunday, 24 May 2020, 22:01:00
Oxford University Coronavirus Vaccine Trial Chance Of Success Cut From 80% To Only 50% Tyler Durden Sun, 05/24/2020 – 18:01 Following the disappointing late Friday publication of a pivotal study by the New England Journal of Medicine , according to which Gilead’s Remdeisivir presented no marked benefit for those Coronavirus patients who were healthier and didn’t need oxygen or those who were sicker, requiring a ventilator or a heart-lung bypass machine , and that the only statistically significant improvement was observed in patients on supplemental oxygen, while also concluding that ” given high mortality despite the use of remdesivir, it is clear that treatment with an antiviral drug alone is not likely to be sufficient”, overnight there was more bad news, this time from the world of potential coronavirus vaccines, after the Telegraph reported that the Oxford University team in charge of developing a vaccine said a recent decline in the infection rate will make it increasingly difficult to prove whether it’s been successful. “It’s a race against the virus disappearing, and against time,” Professor Adrian Hill, director of the university’s Jenner Institute, told the newspaper. “We said earlier in the year that there was an 80% chance of developing an effective vaccine by September.
— Zero Hedge

The untold story of Moderna as the biotech’s coronavirus vaccine faces a test that could make it one of the most consequential startups of all time (MRNA)

Saturday, 23 May 2020, 11:45:00
The biotech Moderna has skyrocketed to global prominence, leading the world’s race for a coronavirus vaccine. The Cambridge, Massachusetts-based biotech was founded in 2010 with the ambitious goal to develop a new type of medicine. While its platform remains unproven, it is now being tested under the brightest possible spotlight of a pandemic. Here’s the inside story of Moderna’s rise, from an offshoot of stem cell research to routinely shattering funding records on its way to biotech’s top ranks. The biotech has spent a decade working to meet this moment, and investors have sent its stock soaring to a valuation of almost $30 billion. The next few months will be a defining period for the future of Moderna. Visit Business Insider’s homepage for more stories . In its short corporate history, Moderna has grown accustomed to breaking records. A $450 million funding round in 2015 was a record for the biotech industry. Moderna raised even more the next year. And its 2018 initial public offering was the largest ever for a biotech .
— Business Insider